Zomedica Corp. · OTC:ZOMDF
Zomedica — The East Coast Family Office & High Net Worth Conference, October 24th, 2023
25 slides from Zomedica's conference presentation, Oct 24, 2023
Slide 1: Peter Donato, Chief Financial Officer, October 2023
Peter Donato Chief Financial Officer pdonato@zomedica.com www.zomedica.com October 2023 © 2023 Zomedica Corp
Slide 2: Forward Looking Statements
Forward Looking Statements These materials have been prepared for informational purposes only in relation to Zomedica and are not, under any circumstances, to be construed as an offering of any securities for sale directly or indirectly in any province or territory of Canada, in the United States or
Slide 3: Investment Highlights
Investment Highlights Attractive Industry: Humanization of pets drives recession resistant market growth. Differentiated Solutions: Innovative technology to improve care, practice workflow & customer economics Experienced Management Team: Start-up mentality focused on flawless execution Manufacturin
Slide 4: Market Analysis
Market Analysis • Vet Service Market is Significant: • Global veterinary service market valued at Therapeutic devices and point of care diagnostics are fastest growing segment in Vet Service market. $97.3 billion in 2020 1 • Veterinary services in the U.S. are projected to surpass $62.2 billion in 2
Slide 5: Challenges our Customers face
Challenges our Customers face- “It’s Never Been Harder To Practice Veterinary Medicine” Labor, both DVM and staff are a critical issue causing While pharmacy revenue remains important Veterinarians to work more than ever. Vet practices are losing out to online retail on critical chronic refills and
Slide 6: Zomedica Mission & Vision
Zomedica Mission & Vision PulseVet® Zomedica is bringing innovative Shock Wave System diagnostic and therapeutic technology to Veterinarians to Assisi LOOP ® improve the quality of care for the pet, the satisfaction of the pet parent, and the workflow, cash flow and profitability of the practice. TR
Slide 7: Experienced Leadership
Experienced Leadership Larry Heaton - Chief Executive Officer • More than 35 years of executive leadership and operations experience • Extensive focus on business and product development at both large-cap and early-stage medical companies • Experience includes leadership positions w/ Flowonix, Cardi
Slide 8: Zomedica Growth by Acquisition
Zomedica Growth by Acquisition Total Annual Cumulative Y/Y Deal Date Type Cost Addressable Annual Growth Market (TAM) TAM (thru 6/30/23) TRUFORMA® March 2021 License $775M $0.8B +145% Stock PulseVet® October 2021 $71M $150M $0.9B +46% acquisition Revo2 / Asset Launched July 1, 2022 $6M (1) $1.3B $2.
Slide 9: US Total Addressable Market
US Total Addressable Market 32,000 Total Addressable Market: Total Addressable Market: Small Animal & Mixed Practices U.S. Annual Recurring Revenue & U.S. Capital Revenue 2,500 Equine Practices(2) PulseVet® $150M PulseVet Trodes $1B $2,000 TRUFORMA® TRUVIEWTM $32,000 / System $775M $1.3B Assays $495
Slide 10: Zomedica Commercial Platforms
Zomedica Commercial Platforms Therapeutic Devices Diagnostics The PulseVet® shock wave technology has been clinically proven to enhance the quality and speed of healing in various musculoskeletal indications, from ligament and tendon injuries to osteoarthritis, lick granulomas, LS disease, and non-u
Slide 11: myZomedica Experience
myZomedica.com • Plug and play IoT experience. No clinic networking required. myZomedica Experience • View test results remotely from any internet connected desktop, laptop, or tablet. • Rules based test result views anticipating clinician needs for interpretation. • Online repository of useful devi
Slide 12: Zomedica Revenue Up 44% 2Q22 to 2Q23
Zomedica Revenue Up 44% 2Q22 to 2Q23 All Figures In Thousands Total Revenue(1) Qorvo and VetGuardian Agreements PulseVet, Revo, and Assisi Deals Closed International Revenue: 20-25% from: PulseVet Assisi Planned for 2024 Int’l Launch: TRUFORMA TRUVIEW VetGuardian TRUFORMA Launch (1) Please see Zomed
Slide 13: Driven Organically, Through M&A, and Across Segments
Driven Organically, Through M&A, and Across Segments All Figures Are Dollars In Thousands (1) Product lines launched or acquired more than 12 months ago (TRUFORMA and PulseVet). (2) Product lines launch or acquired within the past 12 months (Assisi, Revo, and VetGuardian). (3) Please see Zomedica’s
Slide 14: Sniffing out Future Technologies
Sniffing out Future Technologies
Slide 15: Our Objectives – Zomedica's Five Pillars for Ongoing M&A
Our Objectives – Zomedica’s Five Pillars for Ongoing M&A Improving the quality of care for the pet 1 • • • Reference lab accuracy diagnostics at point of care Cloud based integrated patient monitoring Clinically validated treatments that work; Benefits are observable Improving the satisfaction of th
Slide 16: Product Line Overview
Product Line Overview 16
Slide 17: TRUFORMA – Reference Lab Accuracy at the Point of Care
TRUFORMA® – Reference Lab Accuracy at the Point of Care • Based on clinically proven, highly sensitive Bulk Acoustic Wave (BAW) technology • Developed and commercialized by Qorvo in Telecom & Aerospace industries TRUFORMA • FDA emergency use authorization for COVID testing by Qorvo Biotechnologies D
Slide 18: TRUFORMA Assay Development Targets
TRUFORMA® Assay Development Targets On the Market In Development Potential Opportunities Adrenal & Thyroid Panel for Dogs Expanding into high value Point Becoming a broad-based Point and Cats of Care solutions of Care lab solution 2024 => 3Q23 6 Now Available Launch Adrenal & Thyroid Potential Targe
Slide 19: TRUVIEW Digital Cytology Platform & Pathology Services
TRUVIEW Digital Cytology Platform & Pathology Services TRUVIEWTM Digital Microscopy w/ TRUprepTM fully automated slide preparation • Innovative digital imaging system with LiquiViewTM liquid lens optics provide best-in-class visualization • First in class automated slide preparation • Improves workf
Slide 20: Zomedica's VetGuardian Wireless Monitoring System
Zomedica’s VetGuardianTM Wireless Monitoring System Zomedica Acquired Structured Monitoring products Sept 5, 2023 The VetGuardian System • 24-hour no touch vital signs monitoring capability provides improved care for pet patients, enhanced workflow and new revenue stream for practice Continuous Wave
Slide 21: PulseVet - Global Leader in Shock Wave Therapy
PulseVet - Global Leader in Shock Wave Therapy • Global leader in shock wave therapy for wound healing, and difficult to treat injuries • 14 Published clinical studies, including randomized control trials • 20 small animal applications; 40 equine applications • Clinical studies underway to extend bo
Slide 22: Acquired Capabilities: Assisi Product Line
Assisi Product Line – Complements PulseVet® with in home supplemental treatment Assisi Loop® & Loop Lounge • Sold for pain and inflammation from OA and wound healing • "Re-sposable" requiring replacement after 150 treatments Newly Launched Line Extensions • Dental loop indicated for gum disease and
Slide 23: 1st Half 2023 Financial Highlights
1st Half 2023 Financial Highlights Revenue: Non-GAAP Adjusted EBITDA: As Presented One-Time Items Adjusted 2021: $4M 2022: $19M First Half ‘23 6/30/2023 6/30/2023 6/30/2023 YOY Growth: Net revenue Cost of revenue $ 11,502 3,619 $ — — $ 11,502 3,619 44% Gross profit 7,883 — 7,883 Operating expenses 2
Slide 24: Why Invest In Zomedica?
Why Invest In Zomedica? Veteran management team Significant Revenue Growth - TRUFORMA: 300% vs. 2021 Track record, leadership & leading revenue growth and - PulseVet: 31% vs. 2021 capital to continue acquisitions driving to profitability in large, thru 3Q2022 of complementary products to growing, re
Slide 25: Appendix Endnotes
Appendix Endnotes • (1) JP Morgan coverage initiation report on Idexx and Heska, January 2021 • (2) JP Morgan AH Industry overview Jan 2021 • (3) Credit Suisse Animal Health Industry Primer, June 2021 Pg 16 • Grandview Research August 2021 • Global Market Insights • 2016 pet owner survey conducted b
Zomedica — The East Coast Family Office & High Net Worth Conference, October 24th, 2023 on 6ix